Calvin Zippin

Last updated
Calvin Zippin
Calvin Zippin color.jpg
Born
Calvin (Kalman) Zippin

(1926-07-17) July 17, 1926 (age 98)
Albany, New York
NationalityAmerican
Alma mater State University New York at Albany
Johns Hopkins University
Known forZippin estimator
Cancer Registries
Cancer epidemiology
Surveillance, Epidemiology, and End Results (SEER) program of the National Cancer Institute (NCI) [1]
SpousePatricia Jayne Schubert (1930 – 2015) m. February 9, 1964 [2]
ChildrenDavid Benjamin Zippin
Jennifer Dorothy (Zippin) Kontzer
Awards1969 Distinguished Alumnus Award, State University New York at Albany
1980 Fellow American Statistical Association
2003 National Cancer Institute Lifetime Achievement and Leadership Award [3]
Scientific career
Fields Biostatistics
Epidemiology
Cancer Registry
Institutions UCSF School of Medicine, Johns Hopkins University
Thesis An Evaluation of the Removal Method of Estimating Animal Populations  (1953)
Doctoral advisor William G. Cochran [4]

Calvin Zippin (born July 17, 1926) is a cancer epidemiologist and biostatistician, and Professor Emeritus in the Department of Epidemiology and Biostatistics at the University of California School of Medicine in San Francisco (UCSF). He is a Fellow of the American Statistical Association, the American College of Epidemiology and the Royal Statistical Society of Great Britain. His doctoral thesis was the basis for the Zippin Estimator, a procedure for estimating wildlife populations using data from trapping experiments. [5] He was a principal investigator in the Surveillance, Epidemiology, and End Results (SEER) program of the National Cancer Institute (NCI) which assesses the magnitude and nature of the cancer problem in the United States. [6] In 1961, he created training programs for cancer registry personnel, which he conducted nationally and internationally. He carried out research on the epidemiology and rules for staging of various cancers. He received a Lifetime Achievement and Leadership Award from the NCI in 2003.

Contents

Early life and education

Zippin was born on July 17, 1926, in Albany, New York, United States, the son of Samuel and Jennie (Perkel) Zippin. He received an AB degree magna cum laude in biology and mathematics, from the State University of New York at Albany in 1947. He was a research assistant at the Sterling-Winthrop Research Institute in Rensselaer, New York beginning in 1947. [7] He was awarded a Doctor of Science degree in Biostatistics by the Johns Hopkins School of Hygiene and Public Health in Baltimore, Maryland in 1953. [4]

His thesis advisor was William G. Cochran [7] a statistician known for Cochran’s theorem, Cochran-Mantel-Haenzel Test and author of standard biostatistical texts: “Experimental Designs” [8] and “Sampling Techniques”. [9] Zippin’s doctoral thesis, An Evaluation of the Removal Method of Estimating Animal Populations became the basis for the Zippin Estimator, and has been used for estimating populations of a wide variety of animal species. [5] It is considered among the easiest and most accurate methods for estimating animal populations in the wild. [10]

Career

At the Sterling-Winthrop Research Institute, Zippin performed various laboratory and statistical duties under Lloyd C. Miller, Ph.D., later Director of Revision (1950-1970) of the United States Pharmacopoeia. Dr. Miller encouraged Zippin to pursue a career in statistics which led to his graduate work at Johns Hopkins [7] where he also held an appointment as a Research Assistant in Biostatistics from 1950 to 1953. Following graduate school, Zippin became an instructor in biostatistics (1953-1955) at the School of Public Health, University of California, Berkeley. He moved to the School of Medicine at the University of California, San Francisco where, at the level of assistant professor, he held appointments in the Cancer Research Institute and the Department of Preventive Medicine. With further advancement, in 1967 he became Professor of Epidemiology in the Cancer Research Institute, Department of Epidemiology and Biostatistics, and Department of Pathology. Since 1991 he has been Professor Emeritus. [11]

Zippin was a Visiting associate professor of statistics, Stanford University, Palo Alto, CA (1962); National Institutes of Health (NIH) Special Postdoctoral Fellow, London School of Hygiene and Tropical Medicine (1964-1965); Visiting Research Worker, Middlesex Hospital Medical School, London (1975); Research Advisor, Assaf Harofeh Medical Center, Zerifin, Israel (1976-2010); Faculty Advisor, Regional Cancer Centre, Trivandrum, Kerala State, India (1984-1991).[ citation needed ]

Research

Zippin’s doctoral thesis became the basis for the Zippin Estimator, a mathematical procedure for estimating wildlife population size based on capture and removal of sequentially trapped animal samples. [5] The method was explored by P. A. P. Moran (1951) [12] and its properties elaborated by Zippin in 1956 [13] and 1958. [14] [5] : 8  [15]

Zippin has done extensive research on cancer staging, particularly cancer of the breast [16] [17] [18] [19] and colon-rectum [20] with the American Joint Committee on Cancer and the International Union Against Cancer. He has published on the epidemiology of breast, [21] [22] uterine, [23] and nasopharyngeal cancer, [24] late effects of radiation, [23] [25] [26] and survival patterns in acute lymphocytic [27] [28] and chronic lymphocytic leukemia. [29] His 1960 [18] and 1966 [19] JNCI breast cancer staging articles were included in the "Yearbook of Cancer" compendium of the most influential cancer publications for those years, respectively.

Zippin collaborated with Peter Armitage, [30] extending a mathematical model assuming survival time of cancer patients to follow an exponential distribution whose key parameter (expected survival time) is linearly related to a measure of the severity (e.g., white blood count in leukemia) of disease. The extension provided for the common situation where some patients were still alive and their limited (censored) survival information could be used in estimating the value of the desired parameter.

From 1973 to 1995, Zippin collaborated with Dr. Yoav Horn [31] comparing characteristics of Arab cancer patients living on the West Bank, their disease and survival with those of patients in Israel and the United States. This project documented the need for improved treatment facilities and the training of oncologists in that region. Horn, an Israeli oncologist, started two cancer clinics in Nablus and Beit Jala and developed a training program for Arab oncologists for which Dr. Horn received the Sasakawa Health Prize from the World Health Organization in 2000. [32]

Honors and awards

Zippin is a Fellow of the American Statistical Association (1980), American College of Epidemiology (1982), and the Royal Statistical Society of Great Britain (1965). He was President of the Western North American Region of the International Biometric Society (1979-1980) and a member of the Committee of Presidents of Statistical Societies (1979-1981). He is a member of Phi Beta Kappa, Sigma Xi, Delta Omega (honorary public health society), and Signum Laudis (honorary academic society). In 1994, he was elected an honorary Member of the International Association of Cancer Registries, which is administered by the World Health Organization, [33] and the California Cancer Registrars Association. [34] From 1989 to 1995, he served on the Board of Governors of the National Cancer Database (NCDB), a clinical oncology database sourced from hospital registry data which is jointly sponsored by the American College of Surgeons and the American Cancer Society. [35] Zippin was on the editorial boards of Statistics in Medicine [36] and the Journal of Soviet Oncology. [37] [38] He received the Distinguished Alumnus Award from the State University of New York at Albany (1969) and a Lifetime Achievement and Leadership Award from the National Cancer Institute (2003). [7] Dr. Zippin appeared on the cover of the journal “Cancer Research” in recognition of his contributions to the NCI’s SEER (Surveillance, Epidemiology, and End Results ) program. [39]

Related Research Articles

<span class="mw-page-title-main">Leukemia</span> Blood cancers forming in the bone marrow

Leukemia is a group of blood cancers that usually begin in the bone marrow and produce high numbers of abnormal blood cells. These blood cells are not fully developed and are called blasts or leukemia cells. Symptoms may include bleeding and bruising, bone pain, fatigue, fever, and an increased risk of infections. These symptoms occur due to a lack of normal blood cells. Diagnosis is typically made by blood tests or bone marrow biopsy.

<span class="mw-page-title-main">Lymphoma</span> Hematologic cancer that affects lymphocytes

Lymphoma is a group of blood and lymph tumors that develop from lymphocytes. The name typically refers to just the cancerous versions rather than all such tumours. Signs and symptoms may include enlarged lymph nodes, fever, drenching sweats, unintended weight loss, itching, and constantly feeling tired. The enlarged lymph nodes are usually painless. The sweats are most common at night.

<span class="mw-page-title-main">Chronic lymphocytic leukemia</span> Bone marrow cancer in which lymphocytes are overproduced

Chronic lymphocytic leukemia (CLL) is a type of cancer in which the bone marrow makes too many lymphocytes. Early on, there are typically no symptoms. Later, non-painful lymph node swelling, feeling tired, fever, night sweats, or weight loss for no clear reason may occur. Enlargement of the spleen and low red blood cells (anemia) may also occur. It typically worsens gradually over years.

<span class="mw-page-title-main">Alcohol and cancer</span> Relationship between cancer and the consumption of alcohol

Alcohol and cancer have a complex relationship. Alcohol causes cancers of the oesophagus, liver, breast, colon, oral cavity, rectum, pharynx, and larynx, and probably causes cancers of the pancreas. Cancer risk can occur even with light to moderate drinking. The more alcohol is consumed, the higher the cancer risk, and no amount can be considered completely safe.

<span class="mw-page-title-main">Medullary breast carcinoma</span> Rare type of breast cancer

Medullary breast carcinoma is a rare type of breast cancer that is characterized as a relatively circumscribed tumor with pushing, rather than infiltrating, margins. It is histologically characterized as poorly differentiated cells with abundant cytoplasm and pleomorphic high grade vesicular nuclei. It involves lymphocytic infiltration in and around the tumor and can appear to be brown in appearance with necrosis and hemorrhage. Prognosis is measured through staging but can often be treated successfully and has a better prognosis than other infiltrating breast carcinomas.

<span class="mw-page-title-main">Epidemiology of cancer</span> The study of factors in cancer causes and treatments

The epidemiology of cancer is the study of the factors affecting cancer, as a way to infer possible trends and causes. The study of cancer epidemiology uses epidemiological methods to find the cause of cancer and to identify and develop improved treatments.

<span class="mw-page-title-main">Edison Liu</span>

Edison T. Liu is an American chemist who is the former president and CEO of The Jackson Laboratory, and the former director of its NCI-designated Cancer Center (2012-2021). Before joining The Jackson Laboratory, he was the founding executive director of the Genome Institute of Singapore (GIS), chairman of the board of the Health Sciences Authority, and president of the Human Genome Organization (HUGO) (2007-2013). As the executive director of the GIS, he brought the institution to international prominence as one of the most productive genomics institutions in the world.

<span class="mw-page-title-main">Peter Boyle (epidemiologist)</span> British epidemiologist (1951–2022)

Peter Boyle, FRSE FFPH FRCPS(Glas) FRCP(Edin) FMedSci, was a British epidemiologist. He conducted research on globalisation of cancer, where he showed the dramatic increase of cancer in low- and medium income countries.

Philippe Autier is a Belgian epidemiologist. He is doing research on cancer, where he contributed to the understanding of the role of UV exposure in cancer development.

<span class="mw-page-title-main">Genta (company)</span> Biotechnology company

Genta Incorporated was a biopharmaceutical company started in La Jolla, California, which discovered and developed innovative drugs for the treatment of patients with cancer. Founded in 1989 by a highly skilled entrepreneur, the company focused on a novel technology known as antisense, which targets gene products that are associated with the onset and progression of serious diseases. At that time, only Ionis Pharmaceuticals, Inc. was conducting significant research with this technology. Antisense is a short span of oligonucleotides – modified DNA structures ranging from about 12-24 bases that selectively bind to specific RNA. The intent is to block expression of an aberrant protein that contributes to the disease of interest. Genta in-licensed three different antisense molecules that blocked Bcl-2, a fibroblast growth factor (FGF), and the gene c-myb, respectively.

Alan Ashworth, FRS is a British molecular biologist, noted for his work on genes involved in cancer susceptibility. He is currently the President of the UCSF Helen Diller Family Comprehensive Cancer Center at the University of California, San Francisco, a multidisciplinary research and clinical care organisation that is one of the largest cancer centres in the Western United States. He was previously CEO of the Institute of Cancer Research (ICR) in London.

<span class="mw-page-title-main">Cancer biomarker</span> Substance or process that is indicative of the presence of cancer in the body

A cancer biomarker refers to a substance or process that is indicative of the presence of cancer in the body. A biomarker may be a molecule secreted by a tumor or a specific response of the body to the presence of cancer. Genetic, epigenetic, proteomic, glycomic, and imaging biomarkers can be used for cancer diagnosis, prognosis, and epidemiology. Ideally, such biomarkers can be assayed in non-invasively collected biofluids like blood or serum.

<span class="mw-page-title-main">Childhood cancer</span> Medical condition

Childhood cancer is cancer in a child. About 80% of childhood cancer cases in high-income countries can be successfully treated via modern medical treatments and optimal patient care. However, only about 10% of children diagnosed with cancer reside in high-income countries where the necessary treatments and care is available. Childhood cancer represents only about 1% of all types of cancers diagnosed in children and adults, It is often more complex than adult cancers with unique biological characteristics and research and treatment is yet very challenging and limited. For this reason, childhood cancer is often ignored in control planning, contributing to the burden of missed opportunities for its diagnoses and management in countries that are low- and mid-income.

High-dose chemotherapy and bone marrow transplant (HDC/BMT), also high-dose chemotherapy with autologous bone marrow transplant, was an ineffective treatment regimen for metastatic breast cancer, and later high-risk breast cancer, that was considered promising during the 1980s and 1990s. With an overall idea that more is better, this process involved taking cells from the person's bone marrow to store in a lab, then to give such high doses of chemotherapy drugs that the remaining bone marrow was destroyed, and then to inject the cells taken earlier back into the body as replacement. It was ultimately determined to be no more effective than normal treatment, and to have significantly higher side effects, including treatment-related death.

Marvin Zelen was Professor Emeritus of Biostatistics in the Department of Biostatistics at the Harvard T.H. Chan School of Public Health (HSPH), and Lemuel Shattuck Research Professor of Statistical Science. During the 1980s, Zelen chaired HSPH's Department of Biostatistics. Among colleagues in the field of statistics, he was widely known as a leader who shaped the discipline of biostatistics. He "transformed clinical trial research into a statistically sophisticated branch of medical research."

<span class="mw-page-title-main">Dimitrios Trichopoulos</span> American-Greek researcher (1938–2014)

Dimitrios Trichopoulos, was a Mediterranean Diet expert and tobacco harms researcher. He was Vincent L. Gregory Professor of Cancer Prevention and Professor of Epidemiology, and a past chair of the Department of Epidemiology, in the Harvard School of Public Health in Boston.

<span class="mw-page-title-main">Nilanjan Chatterjee</span> Biostatistician

Nilanjan Chatterjee is a Bloomberg Distinguished Professor of Biostatistics and Genetic Epidemiology at Johns Hopkins University, with appointments in the Department of Biostatistics in the Bloomberg School of Public Health and in the Department of Oncology in the Sidney Kimmel Comprehensive Cancer Center in the Johns Hopkins School of Medicine. He was formerly the chief of the Biostatistics Branch of the National Cancer Institute's Division of Cancer Epidemiology and Genetics.

Kathleen I. Pritchard, is the head of oncology at Sunnybrook Health Sciences Centre in Toronto, Canada, specializing in breast cancer therapies, and leading the clinical trials division of the centre. She has authored numerous studies on women's health, breast cancer, hormone replacement therapy, public health, and research methodology. According to Thomson Reuters, Pritchard was one of the most cited researchers in the world in 2014 and 2015.

Cancer in adolescents and young adults is cancer which occurs in those between the ages of 15 and 39. This occurs in about 70,000 people a year in the United States—accounting for about 5 percent of cancers. This is about six times the number of cancers diagnosed in children ages 0–14. Globally, nearly 1 million young adults between the ages of 20 and 39 were diagnosed with cancer in 2012, and more than 350,000 people in this age range died from cancer.

Nola M. Hylton is an American oncologist who is Professor of Radiology and Director of the Breast Imaging Research Group at the University of California, San Francisco. She pioneered the usage of magnetic resonance imaging for the detection, diagnosis, and staging of breast cancer by using MRIs to locate tumors and characterize the surrounding tissue.

References

  1. ↑ Zippin, Calvin. "Surveillance Epidemiology and End Results (SEER)". Grantome. Retrieved 1 August 2019.
  2. ↑ "Patricia Zippin 1930 - 2015". SFGate Obituaries. Retrieved 1 August 2019.
  3. ↑ "Johns Hopkins Magazine (1953)". pages.jh.edu. Retrieved 1 August 2019.
  4. 1 2 "1952-1953 ScD Alumni". www.biostat.jhsph.edu. Johns Hopkins School of Public Health. Retrieved 2 August 2019.
  5. 1 2 3 4 White, Gary C.; Anderson, David R.; Burnham, Kenneth P.; Otis, David L. (1 August 1982). Capture-Recapture and Removal Methods for Sampling Closed Populations. Los Alamos National Laboratory. Retrieved 1 August 2019.
  6. ↑ Shambaugh, Evelyn M.; Young, John L.; Zippin, Calvin; Lum, Diane; Ackers, Cheryl; Weiss, Mildred A. (1994). SEER Program - Self-Instructional Manual for Cancer Registrars. Book 7 - Statistics and Epidemiology for Cancer Registrars (PDF) (Volume 7 ed.). Bethesda, MD: National Institutes of Health. Retrieved 26 July 2020.
  7. 1 2 3 4 "Longtime Members Offer Wisdom". Amstat News. American Statistical Association. 1 April 2018. Retrieved 1 August 2019.
  8. ↑ Cochran, William G; Cox, Gertrude May (1957). Experimental designs (2d ed.). Wiley. ISBN   978-0471162049.
  9. ↑ Cochran, William G. (1977). Sampling techniques (3d ed.). John Wiley & Sons. ISBN   978-0471162407.
  10. ↑ Santos, Jair Licío Ferreira; Oliva, Waldyr Muniz (February 1991). "Sobre o procedimento de Zippin para estimar populações de animais". Revista de Saúde Pública. 25 (1): 53–55. doi: 10.1590/s0034-89101991000100011 . PMID   1784963.
  11. ↑ "Emeriti Faculty Association - UCSF Alumni". alumni.ucsf.edu. Archived from the original on 29 April 2020. Retrieved 18 July 2020.
  12. ↑ Moran, P.A.P. (1951). "A mathematical theory of animal trapping". Biometrika. 38 (3–4): 307–311. doi:10.1093/biomet/38.3-4.307.
  13. ↑ Zippin, C (1956). "An evaluation of the removal method of estimating animal populations". Biometrics. 12 (2): 163–189. doi:10.2307/3001759. JSTOR   3001759.
  14. ↑ Zippin, C (1958). "The removal method of population estimation". The Journal of Wildlife Management. 22 (1): 82–90. doi:10.2307/3797301. JSTOR   3797301.
  15. ↑ Otis, David L.; Burnham, Kenneth P.; White, Gary C.; Anderson, David R. (1978). "Statistical Inference from Capture Data on Closed Animal Populations". Wildlife Monographs (62).
  16. ↑ Zippin, C; Wood, DA; Lum, D (1962). "Study of the Joint Committee recommendations for clinical staging of cancer of the breast". CA: A Cancer Journal for Clinicians. 12 (5): 194–9. doi: 10.3322/canjclin.12.5.194 . PMID   14003784. S2CID   19907075.
  17. ↑ Cutler, SJ; Zippin, C; Asire, AJ (February 1969). "The prognostic significance of palpable lymph nodes in cancer of the breast". Cancer. 23 (2): 243–50. doi: 10.1002/1097-0142(196902)23:2<243::aid-cncr2820230201>3.0.co;2-9 . PMID   5764971.
  18. 1 2 Zippin, C; Kohn, HI (1960). "An evaluation of the proposed international clinical staging system for cancer of the breast". Journal of the National Cancer Institute. 25: 13–24. PMID   13847624.
  19. 1 2 Zippin, C (January 1966). "Comparison of the international and American systems for the staging of breast cancer". Journal of the National Cancer Institute. 36 (1): 53–62. PMID   5901528.
  20. ↑ Wood, DA; Robbins, GF; Zippin, C; Lum, D; Stearns, M (March 1979). "Staging of cancer of the colon and cancer of the rectum". Cancer. 43 (3): 961–8. doi: 10.1002/1097-0142(197903)43:3<961::aid-cncr2820430327>3.0.co;2-w . PMID   427737.
  21. ↑ Zippin, C (1969). "The epidemiology of breast cancer". Oncology. 23 (2): 93–8. doi:10.1159/000224471. PMID   5787940.
  22. ↑ Zippin, C; Petrakis, NL (December 1971). "Identification of high risk groups in breast cancer". Cancer. 28 (6): 1381–7. doi: 10.1002/1097-0142(197112)28:6<1381::aid-cncr2820280607>3.0.co;2-z . PMID   4942632.
  23. 1 2 Zippin, C; Lum, D; Kohn, HI; Bailar JC, 3rd (1981). "Late effects of radiation therapy for cancer of the uterine cervix". Cancer Detection and Prevention. 4 (1–4): 487–92. PMID   7349815.{{cite journal}}: CS1 maint: numeric names: authors list (link)
  24. ↑ Zippin, Calvin; Tekawa, Irene; Bragg, Kay; Watson, Dorothy; Linden, George (1962). "Studies on Heredity and Environment in Cancer of the Nasopharynx". Journal of the National Cancer Institute. 29 (3): 483–490.
  25. ↑ Zippin, C; Bailar JC, 3rd; Kohn, HI; Lum, D; Eisenberg, H (October 1971). "Radiation therapy for cervical cancer: late effects on life span and on leukemia incidence". Cancer. 28 (4): 937–42. doi: 10.1002/1097-0142(1971)28:4<937::aid-cncr2820280416>3.0.co;2-0 . PMID   5111744. S2CID   1629103.{{cite journal}}: CS1 maint: numeric names: authors list (link)
  26. ↑ Kohn, HI; Bailar, JC; Zippin, C (March 1965). "Radiation Therapy for Cancer of the Cervix: its Late Effect on the Lifespan as a Function of the Regional Dose". Journal of the National Cancer Institute. 34: 345–61. PMID   14342584.
  27. ↑ Zippin, C; Cutler, SJ; Lum, D (March 1975). "Time trends in survival in acute lymphocytic leukemia". Journal of the National Cancer Institute. 54 (3): 581–6. PMID   1054762.
  28. ↑ Zippin, C; Cutler, SJ; Reeves WJ, Jr; Lum, D (January 1971). "Variation in survival among patients with acute lymphocytic leukemia". Blood. 37 (1): 59–72. doi: 10.1182/blood.V37.1.59.59 . PMID   5312779.
  29. ↑ Zippin, C; Cutler, SJ; Reeves WJ, Jr; Lum, D (September 1973). "Survival in chronic lymphocytic leukemia". Blood. 42 (3): 367–76. doi: 10.1182/blood.V42.3.367.367 . PMID   4725600.
  30. ↑ Zippin, Calvin; Armitage, Peter (December 1966). "Use of Concomitant Variables and Incomplete Survival Information in the Estimation of an Exponential Survival Parameter". Biometrics. 22 (4): 665. doi:10.2307/2528067. JSTOR   2528067.
  31. ↑ Horn, Y; Zippin, C; Salhab, AR; Horani, Y (1991). "Cancer patterns at medical centers in Israel and the West Bank". Oncology. 48 (4): 301–8. doi:10.1159/000226947. PMID   1891172.
  32. ↑ "UCSF professor receives World Health Organization prize for Palestinian cancer treatment program". EurekAlert. American Association for the Advancement of Science. 24 May 2000. Archived from the original on 2 August 2019. Retrieved 2 August 2019.
  33. ↑ "IACR - IACR Honorary Members". www.iacr.com.fr.
  34. ↑ "About Us - CCRA". California Cancer Registars Association. Retrieved 18 July 2020.
  35. ↑ "National Cancer Database". American College of Surgeons. Retrieved 12 June 2021.
  36. ↑ "Statistics in Medicine (Editorial Board)". Statistics in Medicine. 1 (1). Chichester: John Wiley & Sons: 1. 1 January 1982. doi: 10.1002/sim.4780010101 .
  37. ↑ "Journal of Soviet Oncology". Consultants Bureau. 1980. Retrieved 18 July 2020.
  38. ↑ Saunders, Joseph, ed. (January–March 1981). "Editorial Board". Journal of Soviet Oncology. 2 (1). New York, London: Consultants Bureau: 1. ISSN   0270-6296.
  39. ↑ "Calvin Zippin". Cancer Research. 53 (22): cover. 15 November 1993.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.